Get the Stockscreener App
0.58
7.30%
-0.0457
Elevation Oncology Inc stock is traded at $0.58, with a volume of 2.37M.
It is down -7.30% in the last 24 hours and down -0.19% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
See More
Previous Close:
$0.6257
Open:
$0.62
24h Volume:
2.37M
Relative Volume:
3.07
Market Cap:
$34.29M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
-0.162
EPS:
-3.58
Net Cash Flow:
$-38.34M
1W Performance:
-8.82%
1M Performance:
-0.19%
6M Performance:
-79.02%
1Y Performance:
+26.03%
1-Day Range:
$0.55
$0.66
1-Week Range:
$0.55
$0.70
52-Week Range:
$0.4401
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Compare ELEV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.58 | 34.29M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| May-30-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
Elevation Oncology Inc Stock (ELEV) Latest News
Items Tagged with 'ESMO IO 2024' - BioWorld Online
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - The Eastern Progress Online
Elevation Oncology nominates HER3 ADC as development candidate - BioWorld Online
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion - ShareCast
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Elevation Oncology Inc licences Synaffix BV’s ADC platform - European Biotechnology News
Synaffix out-licenses ADC technology to Elevation Oncology - The Pharma Letter
Elevation Oncology selects EO-1022 as HER3 ADC candidate - Investing.com
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors - PR Newswire
Elevation Oncology Unveils Promising HER3 ADC Candidate for Multiple Cancer Types - StockTitan
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 - PR Newswire
Elevation Oncology Shares Tumble 39% On $50 Mln Stock-And-Warran… - Marketscreener.com
ELEVElevation Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Five things for pharma marketers to know for Friday morning - MM+M Online
Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com
OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Elevatio - GuruFocus.com
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com
Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com
Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks
Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan
Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Zacks Investment Research
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View - Yahoo Finance
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN
Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News
Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex
It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex
Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com
Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily
Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):